Oncolytics Biotech Inc. (ONCY)
USD 0.55
(0.0%)
USD 0.55
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 33.79 Million CAD | 25.51% |
| 2022 | 26.92 Million CAD | 2.63% |
| 2021 | 26.23 Million CAD | 3.05% |
| 2020 | 25.45 Million CAD | 23.03% |
| 2019 | 20.69 Million CAD | 24.19% |
| 2018 | 16.66 Million CAD | 6.77% |
| 2017 | 15.6 Million CAD | 2.03% |
| 2016 | 15.29 Million CAD | 9.89% |
| 2015 | 13.91 Million CAD | -26.06% |
| 2014 | 18.82 Million CAD | -21.24% |
| 2013 | 23.89 Million CAD | -34.86% |
| 2012 | 36.68 Million CAD | 27.74% |
| 2011 | 28.72 Million CAD | 85.23% |
| 2010 | 15.5 Million CAD | -8.81% |
| 2009 | 17 Million CAD | 23.59% |
| 2008 | 13.75 Million CAD | -18.33% |
| 2007 | 16.84 Million CAD | 8.71% |
| 2006 | 15.49 Million CAD | 16.39% |
| 2005 | 13.31 Million CAD | -0.14% |
| 2004 | 13.33 Million CAD | 92.34% |
| 2003 | 6.93 Million CAD | -0.41% |
| 2002 | 6.96 Million CAD | -2.48% |
| 2001 | 7.13 Million CAD | 44.02% |
| 2000 | 4.95 Million CAD | 758.31% |
| 1999 | 577.37 Thousand CAD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 7.82 Million CAD | -7.94% |
| 2024 Q1 | 8.6 Million CAD | -1.59% |
| 2023 Q3 | 11.04 Million CAD | 54.3% |
| 2023 Q4 | 8.74 Million CAD | -20.87% |
| 2023 FY | 33.38 Million CAD | 24.01% |
| 2023 Q1 | 6.73 Million CAD | -20.85% |
| 2023 Q2 | 7.16 Million CAD | 6.33% |
| 2022 Q3 | 6.05 Million CAD | 0.23% |
| 2022 Q4 | 8.5 Million CAD | 40.4% |
| 2022 Q1 | 6.31 Million CAD | -15.36% |
| 2022 FY | 26.92 Million CAD | 2.63% |
| 2022 Q2 | 6.04 Million CAD | -4.18% |
| 2021 Q1 | 5.9 Million CAD | -26.9% |
| 2021 Q2 | 6.72 Million CAD | 13.95% |
| 2021 Q3 | 6.15 Million CAD | -8.46% |
| 2021 Q4 | 7.45 Million CAD | 21.12% |
| 2021 FY | 26.23 Million CAD | 3.05% |
| 2020 Q1 | 5.52 Million CAD | -20.45% |
| 2020 Q2 | 5.54 Million CAD | 0.45% |
| 2020 Q3 | 6.31 Million CAD | 13.85% |
| 2020 Q4 | 8.07 Million CAD | 27.81% |
| 2020 FY | 25.45 Million CAD | 23.03% |
| 2019 FY | 20.69 Million CAD | 24.19% |
| 2019 Q2 | 5.3 Million CAD | 6.42% |
| 2019 Q3 | 3.45 Million CAD | -34.98% |
| 2019 Q1 | 4.98 Million CAD | 2.16% |
| 2019 Q4 | 6.94 Million CAD | 101.13% |
| 2018 Q2 | 3.68 Million CAD | -21.57% |
| 2018 Q1 | 4.69 Million CAD | 1.29% |
| 2018 Q4 | 4.88 Million CAD | 43.73% |
| 2018 FY | 16.66 Million CAD | 6.77% |
| 2018 Q3 | 3.39 Million CAD | -7.78% |
| 2017 Q4 | 4.63 Million CAD | 52.73% |
| 2017 FY | 15.6 Million CAD | 2.03% |
| 2017 Q3 | 3.03 Million CAD | -30.41% |
| 2017 Q2 | 4.36 Million CAD | 22.27% |
| 2017 Q1 | 3.56 Million CAD | -31.74% |
| 2016 Q4 | 5.22 Million CAD | 55.38% |
| 2016 Q2 | 2.61 Million CAD | -35.97% |
| 2016 Q1 | 4.08 Million CAD | 15.6% |
| 2016 FY | 15.29 Million CAD | 9.89% |
| 2016 Q3 | 3.36 Million CAD | 28.58% |
| 2015 Q1 | 3.6 Million CAD | -5.33% |
| 2015 Q2 | 3.89 Million CAD | 7.91% |
| 2015 FY | 13.91 Million CAD | -26.06% |
| 2015 Q4 | 3.53 Million CAD | 22.71% |
| 2015 Q3 | 2.88 Million CAD | -26.01% |
| 2014 FY | 18.82 Million CAD | -21.24% |
| 2014 Q1 | 5.56 Million CAD | -5.08% |
| 2014 Q2 | 4.76 Million CAD | -14.45% |
| 2014 Q4 | 3.81 Million CAD | -18.51% |
| 2014 Q3 | 4.67 Million CAD | -1.84% |
| 2013 Q3 | 6.22 Million CAD | 21.45% |
| 2013 Q4 | 5.86 Million CAD | -5.73% |
| 2013 Q1 | 6.68 Million CAD | -21.66% |
| 2013 FY | 23.89 Million CAD | -34.86% |
| 2013 Q2 | 5.12 Million CAD | -23.3% |
| 2012 FY | 36.68 Million CAD | 27.74% |
| 2012 Q4 | 8.52 Million CAD | -8.33% |
| 2012 Q3 | 9.3 Million CAD | -9.45% |
| 2012 Q2 | 10.27 Million CAD | 19.78% |
| 2012 Q1 | 8.57 Million CAD | 37.7% |
| 2011 Q2 | 6.55 Million CAD | 59.85% |
| 2011 Q1 | 4.09 Million CAD | 23.69% |
| 2011 Q3 | 6.33 Million CAD | -3.32% |
| 2011 FY | 28.72 Million CAD | 85.23% |
| 2011 Q4 | 6.22 Million CAD | -1.65% |
| 2010 Q3 | 4.02 Million CAD | -7.67% |
| 2010 Q4 | 3.31 Million CAD | -17.71% |
| 2010 Q1 | 4.15 Million CAD | 187.15% |
| 2010 FY | 15.5 Million CAD | -8.81% |
| 2010 Q2 | 4.36 Million CAD | 5.06% |
| 2009 FY | 17 Million CAD | 23.59% |
| 2009 Q2 | 4.33 Million CAD | 9.15% |
| 2009 Q3 | 2.69 Million CAD | -37.83% |
| 2009 Q4 | 1.44 Million CAD | -46.41% |
| 2009 Q1 | 3.97 Million CAD | 702.75% |
| 2008 Q4 | 495.14 Thousand CAD | -88.24% |
| 2008 Q1 | 3.49 Million CAD | -19.54% |
| 2008 Q2 | 5.48 Million CAD | 56.98% |
| 2008 FY | 13.75 Million CAD | -18.33% |
| 2008 Q3 | 4.21 Million CAD | -23.27% |
| 2007 Q1 | 3.48 Million CAD | -32.27% |
| 2007 Q3 | 4.06 Million CAD | 0.37% |
| 2007 Q2 | 4.04 Million CAD | 16.34% |
| 2007 FY | 16.84 Million CAD | 8.71% |
| 2007 Q4 | 4.34 Million CAD | 6.89% |
| 2006 FY | 15.49 Million CAD | 16.39% |
| 2006 Q1 | 2.17 Million CAD | -14.52% |
| 2006 Q2 | 3.32 Million CAD | 52.38% |
| 2006 Q4 | 5.13 Million CAD | 37.38% |
| 2006 Q3 | 3.74 Million CAD | 12.66% |
| 2005 Q4 | 2.54 Million CAD | -39.44% |
| 2005 Q2 | 3.03 Million CAD | 16.61% |
| 2005 FY | 13.31 Million CAD | -0.14% |
| 2005 Q3 | 4.2 Million CAD | 38.51% |
| 2005 Q1 | 2.6 Million CAD | -37.85% |
| 2004 Q1 | 2.84 Million CAD | 38.26% |
| 2004 Q3 | 3.03 Million CAD | -10.02% |
| 2004 Q2 | 3.37 Million CAD | 18.86% |
| 2004 Q4 | 4.19 Million CAD | 38.05% |
| 2004 FY | 13.33 Million CAD | 92.34% |
| 2003 Q1 | 1.15 Million CAD | -34.24% |
| 2003 Q2 | 1.83 Million CAD | 58.99% |
| 2003 Q4 | 2.05 Million CAD | 6.71% |
| 2003 Q3 | 1.92 Million CAD | 4.65% |
| 2003 FY | 6.93 Million CAD | -0.41% |
| 2002 FY | 6.96 Million CAD | -2.48% |
| 2002 Q1 | 1.49 Million CAD | -52.88% |
| 2002 Q4 | 1.75 Million CAD | -20.49% |
| 2002 Q3 | 2.21 Million CAD | 47.93% |
| 2002 Q2 | 1.49 Million CAD | 0.21% |
| 2001 Q1 | 785.9 Thousand CAD | -32.53% |
| 2001 Q4 | 3.16 Million CAD | 46.6% |
| 2001 Q3 | 2.16 Million CAD | 111.2% |
| 2001 FY | 7.13 Million CAD | 44.02% |
| 2001 Q2 | 1.02 Million CAD | 30.17% |
| 2000 Q3 | 1.84 Million CAD | 19.59% |
| 2000 Q1 | 408.99 Thousand CAD | 0.0% |
| 2000 Q4 | 1.16 Million CAD | -36.76% |
| 2000 FY | 4.95 Million CAD | 758.31% |
| 2000 Q2 | 1.54 Million CAD | 276.55% |
| 1999 FY | 577.37 Thousand CAD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Absci Corporation | 73.66 Million USD | 54.129% |
| Adaptive Biotechnologies Corporation | 321.75 Million USD | 89.498% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 98.123% |
| Alzamend Neuro, Inc. | 9.93 Million USD | -240.03% |
| Apollomics, Inc. | 54.14 Million USD | 37.586% |
| 180 Life Sciences Corp. | 13.47 Million USD | -150.722% |
| Atossa Therapeutics, Inc. | 31.37 Million USD | -7.694% |
| Bicycle Therapeutics plc | 216.92 Million USD | 84.423% |
| Barinthus Biotherapeutics plc | 84.71 Million USD | 60.113% |
| BioXcel Therapeutics, Inc. | 171.9 Million USD | 80.343% |
| CASI Pharmaceuticals, Inc. | 47 Million USD | 28.113% |
| Chimerix, Inc. | 93.38 Million USD | 63.817% |
| CRISPR Therapeutics AG | 463.49 Million USD | 92.71% |
| Contineum Therapeutics, Inc. Class A Common Stock | 33.72 Million USD | -0.187% |
| EyePoint Pharmaceuticals, Inc. | 116.45 Million USD | 70.983% |
| Fortress Biotech, Inc. | 200.19 Million USD | 83.121% |
| Fortress Biotech, Inc. | 200.19 Million USD | 83.121% |
| Gritstone bio, Inc. | 148.37 Million USD | 77.226% |
| Allakos Inc. | 196.05 Million USD | 82.765% |
| Boundless Bio, Inc. Common Stock | 54.79 Million USD | 38.333% |
| Cara Therapeutics, Inc. | 142.46 Million USD | 76.281% |
| Cytokinetics, Incorporated | 173.61 Million USD | 80.536% |
| enGene Holdings Inc. Common Stock | 25.88 Million USD | -30.543% |
| Innoviva, Inc. | 132.15 Million USD | 74.431% |
| Hoth Therapeutics, Inc. | 7.69 Million USD | -339.287% |
| NLS Pharmaceutics AG | 11.8 Million USD | -186.193% |
| RAPT Therapeutics, Inc. | 127.06 Million USD | 73.406% |
| Salarius Pharmaceuticals, Inc. | 12.89 Thousand USD | -261967.628% |
| Terns Pharmaceuticals, Inc. | 102.55 Million USD | 67.052% |
| Vigil Neuroscience, Inc. | 88.86 Million USD | 61.975% |
| ImmuCell Corporation | 9.61 Million USD | -251.354% |
| IDEAYA Biosciences, Inc. | 157.81 Million USD | 78.588% |
| Incyte Corporation | 1.19 Billion USD | 97.162% |
| Inovio Pharmaceuticals, Inc. | 132.55 Million USD | 74.508% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -402.19% |
| Mustang Bio, Inc. | 48.5 Million USD | 30.329% |
| MiMedx Group, Inc. | 229.72 Million USD | 85.291% |
| MEI Pharma, Inc. | 34.78 Million USD | 2.858% |
| MacroGenics, Inc. | 217.21 Million USD | 84.444% |
| Monopar Therapeutics Inc. | 8.83 Million USD | -282.631% |
| Mereo BioPharma Group plc | 35.84 Million USD | 5.722% |
| Marker Therapeutics, Inc. | 17.89 Million USD | -88.856% |
| Marinus Pharmaceuticals, Inc. | 160.54 Million USD | 78.952% |
| Maravai LifeSciences Holdings, Inc. | 171.85 Million USD | 80.337% |
| Minerva Neurosciences, Inc. | 23.08 Million USD | -46.354% |
| NeuroBo Pharmaceuticals, Inc. | 15.88 Million USD | -112.709% |
| NeuroSense Therapeutics Ltd. | 10.28 Million USD | -228.546% |
| NextCure, Inc. | 67.63 Million USD | 50.041% |
| Orchestra BioMed Holdings, Inc. | 54.08 Million USD | 37.517% |
| Ocuphire Pharma, Inc. | 29.6 Million USD | -14.136% |
| Onconetix, Inc. | 34.9 Million USD | 3.198% |
| Oncternal Therapeutics, Inc. | 12.74 Million USD | -165.111% |
| Opthea Limited | 191.96 Million USD | 82.398% |
| Ovid Therapeutics Inc. | 59.67 Million USD | 43.373% |
| Psyence Biomedical Ltd. | 2.75 Million USD | -1128.056% |
| PDS Biotechnology Corporation | 43.04 Million USD | 21.499% |
| Precigen, Inc. | 84.18 Million USD | 59.859% |
| Pieris Pharmaceuticals, Inc. | 72.56 Million USD | 53.434% |
| Prime Medicine, Inc. | 186.63 Million USD | 81.895% |
| PureTech Health plc | 144.59 Million USD | 76.631% |
| Rocket Pharmaceuticals, Inc. | 259.65 Million USD | 86.986% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 98.8% |
| Replimune Group, Inc. | 234.77 Million USD | 85.607% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -290.347% |
| Rigel Pharmaceuticals, Inc. | 130.26 Million USD | 74.059% |
| TransCode Therapeutics, Inc. | 19.41 Million USD | -74.014% |
| Revolution Medicines, Inc. Warrant | 498.76 Million USD | 93.225% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -39.02% |
| Sesen Bio, Inc. | 78.38 Million USD | 56.889% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | 85.223% |
| Solid Biosciences Inc. | 104.31 Million USD | 67.607% |
| Syndax Pharmaceuticals, Inc. | 229.95 Million USD | 85.305% |
| SciSparc Ltd. | 9.01 Million USD | -274.997% |
| Sutro Biopharma, Inc. | 243 Million USD | 86.095% |
| TG Therapeutics, Inc. | 198.47 Million USD | 82.975% |
| Tonix Pharmaceuticals Holding Corp. | 121.4 Million USD | 72.167% |
| Titan Pharmaceuticals, Inc. | 7.46 Million USD | -352.902% |
| Travere Therapeutics, Inc. | 472 Million USD | 92.841% |
| UroGen Pharma Ltd. | 138.88 Million USD | 75.67% |
| Verrica Pharmaceuticals Inc. | 70.59 Million USD | 52.133% |
| XOMA Corporation | 46.46 Million USD | 27.273% |
| Zentalis Pharmaceuticals, Inc. | 252.55 Million USD | 86.62% |
| AbCellera Biologics Inc. | 275.23 Million USD | 87.723% |
| Longboard Pharmaceuticals, Inc. | 56.75 Million USD | 40.466% |
| Cassava Sciences, Inc. | 105.95 Million USD | 68.109% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -142.932% |
| Precision BioSciences, Inc. | 92.46 Million USD | 63.455% |
| Dyadic International, Inc. | 9.15 Million USD | -269.192% |
| Intensity Therapeutics, Inc. | 8.31 Million USD | -306.191% |
| Eton Pharmaceuticals, Inc. | 22.25 Million USD | -51.849% |
| VYNE Therapeutics Inc. | 29.68 Million USD | -13.843% |
| Tenaya Therapeutics, Inc. | 131.19 Million USD | 74.243% |
| IGM Biosciences, Inc. | 265.59 Million USD | 87.277% |
| X4 Pharmaceuticals, Inc. | 107.52 Million USD | 68.573% |
| Acelyrin, Inc. | 422.06 Million USD | 91.994% |
| Abeona Therapeutics Inc. | 17.93 Million USD | -88.366% |
| Ligand Pharmaceuticals Incorporated | 84.32 Million USD | 59.927% |
| Inhibikase Therapeutics, Inc. | 6.73 Million USD | -401.95% |
| Arcturus Therapeutics Holdings Inc. | 245 Million USD | 86.208% |
| Syros Pharmaceuticals, Inc. | 30.77 Million USD | -9.814% |
| Senti Biosciences, Inc. | 94.7 Million USD | 64.32% |
| Mesoblast Limited | 5.9 Million USD | -472.535% |
| Kymera Therapeutics, Inc. | 244.12 Million USD | 86.158% |
| ChromaDex Corporation | 56.37 Million USD | 40.065% |
| BriaCell Therapeutics Corp. | 33.33 Million USD | -1.383% |
| Akebia Therapeutics, Inc. | 201.11 Million USD | 83.198% |
| Dermata Therapeutics, Inc. | 8.04 Million USD | -320.186% |
| Seer, Inc. | 110.49 Million USD | 69.417% |
| Xeris Biopharma Holdings, Inc. | 168.43 Million USD | 79.938% |
| Novavax, Inc. | 779.12 Million USD | 95.663% |
| Virpax Pharmaceuticals, Inc. | 15.68 Million USD | -115.369% |
| Fate Therapeutics, Inc. | 254.04 Million USD | 86.699% |
| Checkpoint Therapeutics, Inc. | 52.25 Million USD | 35.329% |
| Lyell Immunopharma, Inc. | 247.13 Million USD | 86.327% |
| Celcuity Inc. | 66.23 Million USD | 48.98% |
| ContextLogic Inc. | 387 Million USD | 91.268% |
| Phathom Pharmaceuticals, Inc. | 167.82 Million USD | 79.866% |
| HOOKIPA Pharma Inc. | 32.74 Million USD | -3.191% |
| Jazz Pharmaceuticals plc | 3.25 Billion USD | 98.962% |
| Amarin Corporation plc | 272.35 Million USD | 87.593% |
| AnaptysBio, Inc. | 181.56 Million USD | 81.389% |
| Aptevo Therapeutics Inc. | 28.87 Million USD | -17.013% |
| Aptorum Group Limited | 10.56 Thousand USD | -319708.821% |
| Cartesian Therapeutics, Inc. | 110.86 Million USD | 69.521% |
| Arrowhead Pharmaceuticals, Inc. | 445.73 Million USD | 92.419% |
| Ardelyx, Inc. | 169.93 Million USD | 80.116% |
| Celularity Inc. | 215.05 Million USD | 84.287% |
| Omeros Corporation | 94.75 Million USD | 64.337% |
| Humacyte, Inc. | 23.49 Million USD | -43.81% |
| Immunocore Holdings plc | 308.04 Million USD | 89.03% |
| IO Biotech, Inc. | 91.44 Million USD | 63.047% |
| GT Biopharma, Inc. | 13.57 Million USD | -148.902% |
| Cabaletta Bio, Inc. | 74.66 Million USD | 54.74% |
| Summit Therapeutics Inc. | 87.68 Million USD | 61.464% |
| Alaunos Therapeutics, Inc. | 29.46 Million USD | -14.666% |
| Pulmatrix, Inc. | 22.03 Million USD | -53.331% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | 93.874% |
| Evogene Ltd. | 27.79 Million USD | -21.594% |
| CorMedix Inc. | 48.95 Million USD | 30.979% |
| BioLineRx Ltd. | 50.8 Million USD | 33.485% |
| VistaGen Therapeutics, Inc. | 34.08 Million USD | 0.863% |
| Sagimet Biosciences Inc. | 32.74 Million USD | -3.21% |
| PTC Therapeutics, Inc. | 1.31 Billion USD | 97.424% |
| scPharmaceuticals Inc. | 65.17 Million USD | 48.156% |
| Fulcrum Therapeutics, Inc. | 113.46 Million USD | 70.22% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | 90.833% |
| NLS Pharmaceutics AG | 11.8 Million USD | -186.193% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -39.02% |
| Akero Therapeutics, Inc. | 172.87 Million USD | 80.453% |
| Eliem Therapeutics, Inc. | 37.4 Million USD | 9.669% |
| Lisata Therapeutics, Inc. | 25.7 Million USD | -31.442% |
| Stoke Therapeutics, Inc. | 123.55 Million USD | 72.651% |
| Reneo Pharmaceuticals, Inc. | 83.05 Million USD | 59.314% |
| Outlook Therapeutics, Inc. | 53.12 Million USD | 36.395% |
| ProMIS Neurosciences, Inc. | 8.45 Million USD | -299.764% |
| Daré Bioscience, Inc. | 33.6 Million USD | -0.54% |
| bluebird bio, Inc. | 240.23 Million USD | 85.934% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 98.065% |
| DBV Technologies S.A. | 92.16 Million USD | 63.334% |
| Avidity Biosciences, Inc. | 245.15 Million USD | 86.217% |
| Galecto, Inc. | 35.62 Million USD | 5.153% |
| Sensei Biotherapeutics, Inc. | 37.06 Million USD | 8.831% |
| Spruce Biosciences, Inc. | 62.08 Million USD | 45.57% |
| Inhibrx Biosciences, Inc. | 219.83 Million USD | 84.629% |
| GlycoMimetics, Inc. | 39.28 Million USD | 13.986% |
| Arcutis Biotherapeutics, Inc. | 295.72 Million USD | 88.573% |
| ADMA Biologics, Inc. | 66.58 Million USD | 49.252% |
| Clene Inc. | 41.07 Million USD | 17.729% |
| Recursion Pharmaceuticals, Inc. | 352.04 Million USD | 90.402% |
| Aptose Biosciences Inc. | 52.35 Million USD | 35.459% |
| ZyVersa Therapeutics, Inc. | 14.41 Million USD | -134.491% |
| Soligenix, Inc. | 7.79 Million USD | -333.482% |
| Century Therapeutics, Inc. | 56.07 Million USD | 39.735% |
| Kura Oncology, Inc. | 165.8 Million USD | 79.62% |
| Surrozen, Inc. | 18.55 Million USD | -82.162% |
| TScan Therapeutics, Inc. | 114.5 Million USD | 70.49% |
| Ocean Biomedical, Inc. | 2.48 Million USD | -1261.64% |
| CytomX Therapeutics, Inc. | 107.69 Million USD | 68.624% |
| Autolus Therapeutics plc | 196.72 Million USD | 82.823% |
| Mineralys Therapeutics, Inc. | 84.65 Million USD | 60.085% |
| Eterna Therapeutics Inc. | 19.38 Million USD | -74.333% |
| Caribou Biosciences, Inc. | 150.53 Million USD | 77.553% |
| GRI Bio, Inc. | 11.33 Million USD | -198.244% |
| Xenetic Biosciences, Inc. | 7.05 Million USD | -378.918% |
| Janux Therapeutics, Inc. | 81.06 Million USD | 58.315% |
| INmune Bio, Inc. | 29.89 Million USD | -13.028% |
| Heron Therapeutics, Inc. | 172.55 Million USD | 80.417% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | 16.181% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -111.467% |
| Tenax Therapeutics, Inc. | 8.23 Million USD | -310.387% |
| Jaguar Health, Inc. | 42.01 Million USD | 19.574% |
| Entero Therapeutics, Inc. | 15.74 Million USD | -114.661% |
| Milestone Pharmaceuticals Inc. | 62.09 Million USD | 45.584% |
| Clearside Biomedical, Inc. | 32.71 Million USD | -3.289% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | 87.743% |
| Coherus BioSciences, Inc. | 301.45 Million USD | 88.791% |
| Verastem, Inc. | 92.08 Million USD | 63.304% |
| Pliant Therapeutics, Inc. | 185.72 Million USD | 81.806% |
| Histogen Inc. | 14.27 Million USD | -136.764% |
| Aprea Therapeutics, Inc. | 16.04 Million USD | -110.56% |
| ACADIA Pharmaceuticals Inc. | 754.08 Million USD | 95.519% |
| Surrozen, Inc. | 18.55 Million USD | -82.162% |
| Organovo Holdings, Inc. | 14.91 Million USD | -126.557% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -563.84% |
| Cadrenal Therapeutics, Inc. Common Stock | 7.63 Million USD | -342.705% |
| Centessa Pharmaceuticals plc | 178.13 Million USD | 81.031% |
| Hepion Pharmaceuticals, Inc. | 48.44 Million USD | 30.253% |
| BioRestorative Therapies, Inc. | 15.36 Million USD | -119.899% |
| Kronos Bio, Inc. | 128.11 Million USD | 73.625% |
| Turnstone Biologics Corp. | 78.33 Million USD | 56.865% |
| Synaptogenix, Inc. | 8.31 Million USD | -306.442% |
| Tiziana Life Sciences Ltd | 14.58 Million USD | -131.667% |
| Entrada Therapeutics, Inc. | 132.17 Million USD | 74.435% |
| Aurinia Pharmaceuticals Inc. | 253.05 Million USD | 86.647% |
| Exelixis, Inc. | 1.58 Billion USD | 97.87% |
| Nurix Therapeutics, Inc. | 232.05 Million USD | 85.438% |
| Apellis Pharmaceuticals, Inc. | 855.2 Million USD | 96.049% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | 50.929% |
| ESSA Pharma Inc. | 32.13 Million USD | -5.156% |
| TNF Pharmaceuticals, Inc. | 16.36 Million USD | -106.544% |
| Avid Bioservices, Inc. | 25.99 Million USD | -29.985% |
| Insmed Incorporated | 949.26 Million USD | 96.44% |
| MediWound Ltd. | 18.86 Million USD | -79.092% |
| OmniAb, Inc. | 83.89 Million USD | 59.722% |
| Alector, Inc. | 248.8 Million USD | 86.419% |
| Seres Therapeutics, Inc. | 234.3 Million USD | 85.578% |
| Zai Lab Limited | 547.47 Million USD | 93.828% |
| AlloVir, Inc. | 180.93 Million USD | 81.324% |
| Revance Therapeutics, Inc. | 398.65 Million USD | 91.524% |
| ORIC Pharmaceuticals, Inc. | 110.78 Million USD | 69.497% |
| Aura Biosciences, Inc. | 84.99 Million USD | 60.242% |
| Immunic, Inc. | 99.22 Million USD | 65.944% |
| Tarsus Pharmaceuticals, Inc. | 159.01 Million USD | 78.749% |
| Veracyte, Inc. | 357.93 Million USD | 90.559% |
| InMed Pharmaceuticals Inc. | 9.01 Billion USD | 99.625% |
| FibroGen, Inc. | 398.11 Million USD | 91.512% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -137.797% |
| Catalyst Pharmaceuticals, Inc. | 259.42 Million USD | 86.975% |
| Adial Pharmaceuticals, Inc. | 6.88 Million USD | -390.582% |
| Sonnet BioTherapeutics Holdings, Inc. | 7.12 Million USD | -374.211% |
| Cyclacel Pharmaceuticals, Inc. | 25.87 Million USD | -30.603% |
| Amylyx Pharmaceuticals, Inc. | 316.54 Million USD | 89.325% |
| Fortrea Holdings Inc. | 457.3 Million USD | 92.611% |
| KalVista Pharmaceuticals, Inc. | 54.27 Million USD | 37.745% |
| XBiotech Inc. | 37.51 Million USD | 9.915% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | 50.929% |
| Keros Therapeutics, Inc. | 169.27 Million USD | 80.038% |
| SELLAS Life Sciences Group, Inc. | 37.86 Million USD | 10.769% |
| Lyra Therapeutics, Inc. | 20.64 Million USD | -63.645% |
| Foghorn Therapeutics Inc. | 142.06 Million USD | 76.214% |
| Agenus Inc. | 78.18 Million USD | 56.78% |
| Y-mAbs Therapeutics, Inc. | 99.07 Million USD | 65.894% |
| Theravance Biopharma, Inc. | 110.71 Million USD | 69.48% |
| Ultragenyx Pharmaceutical Inc. | 958.24 Million USD | 96.474% |
| Metagenomi, Inc. Common Stock | 28.84 Million USD | -17.147% |
| BioCryst Pharmaceuticals, Inc. | 430.64 Million USD | 92.153% |
| Gain Therapeutics, Inc. | 22.3 Million USD | -51.473% |
| C4 Therapeutics, Inc. | 159.78 Million USD | 78.852% |
| Creative Medical Technology Holdings, Inc. | 5.53 Million USD | -510.944% |
| Chemomab Therapeutics Ltd. | 25.45 Million USD | -32.727% |
| Lantern Pharma Inc. | 17.87 Million USD | -89.013% |
| Eledon Pharmaceuticals, Inc. | 43 Million USD | 21.416% |
| Ainos, Inc. | 12.95 Million USD | -160.881% |
| Pluri Inc. | 22.48 Million USD | -50.316% |
| Prothena Corporation plc | 282.4 Million USD | 88.035% |
| Adaptimmune Therapeutics plc | 200.02 Million USD | 83.106% |
| Rallybio Corporation | 78.93 Million USD | 57.19% |
| Kodiak Sciences Inc. | 277.32 Million USD | 87.815% |
| Cue Biopharma, Inc. | 19.54 Million USD | -72.915% |
| MeiraGTx Holdings plc | 151.07 Million USD | 77.633% |
| Annexon, Inc. | 143.72 Million USD | 76.489% |
| Assembly Biosciences, Inc. | 22.9 Million USD | -47.501% |
| Moderna, Inc. | 6.39 Billion USD | 99.472% |
| Cocrystal Pharma, Inc. | 3.39 Million USD | -896.785% |
| Cidara Therapeutics, Inc. | 86.86 Million USD | 61.099% |
| Blueprint Medicines Corporation | 722.86 Million USD | 95.325% |
| Immix Biopharma, Inc. | 16.14 Million USD | -109.347% |
| CalciMedica, Inc. | 21.81 Million USD | -54.884% |
| Monte Rosa Therapeutics, Inc. | 143.31 Million USD | 76.421% |
| Scholar Rock Holding Corporation | 171.29 Million USD | 80.273% |
| Wave Life Sciences Ltd. | 181.3 Million USD | 81.362% |
| Sana Biotechnology, Inc. | 294.94 Million USD | 88.543% |
| Elicio Therapeutics, Inc. | 34.57 Million USD | 2.268% |
| Adlai Nortye Ltd. American Depositary Shares | 72.55 Million USD | 53.424% |
| Nutriband Inc. | 5.73 Million USD | -489.306% |
| Protara Therapeutics, Inc. | 43.61 Million USD | 22.521% |
| Vor Biopharma Inc. | 126.03 Million USD | 73.189% |
| Roivant Sciences Ltd. | 1.18 Billion USD | 97.158% |
| Alkermes plc | 996.24 Million USD | 96.608% |
| ProKidney Corp. | 151.52 Million USD | 77.699% |
| Applied Therapeutics, Inc. | 74.17 Million USD | 54.444% |
| Arcellx, Inc. | 200.19 Million USD | 83.121% |
| BridgeBio Pharma, Inc. | 614.22 Million USD | 94.499% |
| Tango Therapeutics, Inc. | 150.7 Million USD | 77.577% |
| Galectin Therapeutics Inc. | 38.07 Million USD | 11.244% |
| Atai Life Sciences N.V. | 125.78 Million USD | 73.136% |
| Renovaro Biosciences Inc. | 81.63 Million USD | 58.609% |
| Aerovate Therapeutics, Inc. | 81.4 Million USD | 58.492% |
| MediciNova, Inc. | 10.9 Million USD | -210.002% |
| Praxis Precision Medicines, Inc. | 128.82 Million USD | 73.769% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -365.471% |
| GeoVax Labs, Inc. | 6.02 Million USD | -461.11% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | 92.906% |
| Biomea Fusion, Inc. | 126.13 Million USD | 73.21% |
| RenovoRx, Inc. | 11.39 Million USD | -196.516% |
| Cullinan Oncology, Inc. | 191.08 Million USD | 82.317% |
| Geron Corporation | 70.44 Million USD | 52.029% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -22.511% |
| 4D Molecular Therapeutics, Inc. | 133.59 Million USD | 74.705% |
| Dyne Therapeutics, Inc. | 242.16 Million USD | 86.046% |
| Kiniksa Pharmaceuticals, Ltd. | 262.04 Million USD | 87.105% |
| Royalty Pharma plc | 862.4 Million USD | 96.082% |
| Ventyx Biosciences, Inc. | 207.99 Million USD | 83.754% |
| Imunon, Inc. | 20.31 Million USD | -66.373% |
| BioAtla, Inc. | 129.68 Million USD | 73.944% |
| Allogene Therapeutics, Inc. | 84.91 Million USD | 60.207% |
| Larimar Therapeutics, Inc. | 41.75 Million USD | 19.079% |
| Mersana Therapeutics, Inc. | 207.81 Million USD | 83.74% |
| Structure Therapeutics Inc. | 102.77 Million USD | 67.121% |
| 89bio, Inc. | 151.2 Million USD | 77.652% |
| Kezar Life Sciences, Inc. | 111.17 Million USD | 69.604% |
| aTyr Pharma, Inc. | 12.97 Million USD | -160.351% |
| Aligos Therapeutics, Inc. | 103.65 Million USD | 67.401% |
| Viridian Therapeutics, Inc. | 254.76 Million USD | 86.736% |
| EyeGate Pharmaceuticals, Inc. | 8.22 Million USD | -310.842% |
| Akari Therapeutics, Plc | 16.8 Million USD | -101.065% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -1385.991% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | 88.711% |
| Lexicon Pharmaceuticals, Inc. | 172.86 Million USD | 80.453% |
| Liquidia Corporation | 87.98 Million USD | 61.594% |
| Entera Bio Ltd. | 8.86 Million USD | -281.388% |
| GH Research PLC | 41.22 Million USD | 18.027% |
| Vericel Corporation | 142.04 Million USD | 76.21% |
| Arbutus Biopharma Corporation | 22.54 Million USD | -49.889% |
| Xencor, Inc. | 306.97 Million USD | 88.992% |
| 60 Degrees Pharmaceuticals, Inc. | 4.93 Million USD | -584.915% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -111.467% |
| Coeptis Therapeutics Holdings, Inc. | 20.48 Million USD | -64.915% |
| Vaxcyte, Inc. | 468.04 Million USD | 92.78% |
| Xenon Pharmaceuticals Inc. | 46.54 Million USD | 27.397% |
| Vanda Pharmaceuticals Inc. | 191.79 Million USD | 82.382% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -402.19% |
| Portage Biotech Inc. | 18.19 Million USD | -85.675% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -365.471% |
| Olema Pharmaceuticals, Inc. | 104.96 Million USD | 67.806% |
| OncoCyte Corporation | 25.63 Million USD | -31.806% |
| Qualigen Therapeutics, Inc. | 6.09 Million USD | -454.35% |
| Processa Pharmaceuticals, Inc. | 11.45 Million USD | -194.936% |
| Purple Biotech Ltd. | -22.46 Million USD | 250.403% |
| Tempest Therapeutics, Inc. | 29.15 Million USD | -15.893% |
| Sol-Gel Technologies Ltd. | 30.85 Million USD | -9.501% |
| Rhythm Pharmaceuticals, Inc. | 252.48 Million USD | 86.617% |
| CollPlant Biotechnologies Ltd. | 16.48 Million USD | -105.042% |
| Moleculin Biotech, Inc. | 29.63 Million USD | -14.039% |
| United Therapeutics Corporation | 885.1 Million USD | 96.182% |
| HilleVax, Inc. | 133.34 Million USD | 74.659% |
| Silo Pharma, Inc. | 3.92 Million USD | -761.607% |
| Telomir Pharmaceuticals, Inc. Common Stock | 3.94 Million USD | -757.194% |
| Pharming Group N.V. | 225.49 Million USD | 85.014% |
| Tharimmune, Inc. | 9.45 Million USD | -257.379% |
| Genprex, Inc. | 31.06 Million USD | -8.791% |
| Apogee Therapeutics, Inc. | 93 Million USD | 63.667% |
| Neumora Therapeutics, Inc. Common Stock | 187.52 Million USD | 81.981% |
| Pyxis Oncology, Inc. | 82.19 Million USD | 58.89% |
| XTL Biopharmaceuticals Ltd. | 765 Thousand USD | -4317.124% |
| Virios Therapeutics, Inc. | 5.44 Million USD | -520.369% |
| OKYO Pharma Limited | 8243.57 USD | -409807.358% |
| Savara Inc. | 15.74 Million USD | -114.614% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -93.567% |
| Curis, Inc. | 58.35 Million USD | 42.094% |
| Carmell Therapeutics Corporation | 5.09 Million USD | -563.546% |
| Achieve Life Sciences, Inc. | 27.02 Million USD | -25.05% |
| BeiGene, Ltd. | 3.28 Billion USD | 98.972% |
| Protagonist Therapeutics, Inc. | 153.65 Million USD | 78.008% |
| Erasca, Inc. | 141.52 Million USD | 76.124% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -646.437% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -646.437% |
| Vincerx Pharma, Inc. | 42.6 Million USD | 20.695% |
| Fresh Tracks Therapeutics, Inc. | 14.36 Million USD | -135.215% |
| Acrivon Therapeutics, Inc. Common Stock | 66.7 Million USD | 49.34% |
| Celldex Therapeutics, Inc. | 43.41 Million USD | 22.166% |
| Cogent Biosciences, Inc. | 208.13 Million USD | 83.764% |
| Adicet Bio, Inc. | 152.03 Million USD | 77.775% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | 92.098% |
| Aditxt, Inc. | 25.95 Million USD | -30.212% |
| Adagene Inc. | 41.83 Million USD | 19.221% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -362.251% |
| Quantum-Si incorporated | 111.65 Million USD | 69.737% |
| Acurx Pharmaceuticals, Inc. | 14.57 Million USD | -131.798% |
| Voyager Therapeutics, Inc. | 35.82 Million USD | 5.67% |
| Compugen Ltd. | 43.97 Million USD | 23.152% |
| Generation Bio Co. | 144.46 Million USD | 76.61% |
| Astria Therapeutics, Inc. | 83.03 Million USD | 59.303% |
| Black Diamond Therapeutics, Inc. | 86.46 Million USD | 60.917% |
| Invivyd, Inc. | 205.75 Million USD | 83.577% |
| Relay Therapeutics, Inc. | 72.15 Million USD | 53.171% |
| Quoin Pharmaceuticals, Ltd. | 9.37 Million USD | -260.303% |
| Spero Therapeutics, Inc. | 75.25 Million USD | 55.097% |
| Artelo Biosciences, Inc. | 10.28 Million USD | -228.483% |
| 2seventy bio, Inc. | 289.88 Million USD | 88.343% |
| Instil Bio, Inc. | 85.78 Million USD | 60.61% |
| Capricor Therapeutics, Inc. | 12.8 Million USD | -163.83% |
| Elevai Labs, Inc. Common Stock | 1.13 Million USD | -2878.283% |
| GeoVax Labs, Inc. | 6.02 Million USD | -461.11% |
| Citius Pharmaceuticals, Inc. | 36.73 Million USD | 8.007% |
| Relmada Therapeutics, Inc. | 103.7 Million USD | 67.415% |
| ALX Oncology Holdings Inc. | 170.27 Million USD | 80.155% |
| Vir Biotechnology, Inc. | 767.72 Million USD | 95.599% |
| Evaxion Biotech A/S | 22.27 Million USD | -51.733% |
| Ocular Therapeutix, Inc. | 135.54 Million USD | 75.07% |
| Verve Therapeutics, Inc. | 234.88 Million USD | 85.614% |
| Tyra Biosciences, Inc. | 79.94 Million USD | 57.732% |
| Cingulate Inc. | 22.75 Million USD | -48.472% |
| Galmed Pharmaceuticals Ltd. | -7.49 Million USD | 551.028% |
| Unity Biotechnology, Inc. | 44.66 Million USD | 24.349% |
| Connect Biopharma Holdings Limited | 62.07 Million USD | 45.563% |
| Clearmind Medicine Inc. | 8.74 Million USD | -286.565% |
| Bolt Biotherapeutics, Inc. | 84.07 Million USD | 59.807% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -1052.103% |
| Viking Therapeutics, Inc. | 100.82 Million USD | 66.486% |
| Madrigal Pharmaceuticals, Inc. | 380.49 Million USD | 91.119% |
| ImmunityBio, Inc. | 362.87 Million USD | 90.688% |
| Korro Bio, Inc. | 84.53 Million USD | 60.027% |
| Kineta, Inc. | 21.15 Million USD | -59.723% |
| BioVie Inc. | 31.95 Million USD | -5.761% |
| Codexis, Inc. | 66.51 Million USD | 49.2% |
| Celularity Inc. | 215.05 Million USD | 84.287% |
| Aileron Therapeutics, Inc. | 16.27 Million USD | -107.612% |
| Crinetics Pharmaceuticals, Inc. | 226.62 Million USD | 85.089% |
| Virax Biolabs Group Limited | 6.54 Million USD | -416.125% |
| Cibus, Inc. | 320.3 Million USD | 89.45% |
| IN8bio, Inc. | 30.33 Million USD | -11.385% |
| Adverum Biotechnologies, Inc. | 127.59 Million USD | 73.516% |
| Avalo Therapeutics, Inc. | 640 Thousand USD | -5179.844% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 95.666% |
| Eyenovia, Inc. | 25.4 Million USD | -33.002% |
| Puma Biotechnology, Inc. | 140.31 Million USD | 75.918% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -507.533% |
| Elevation Oncology, Inc. | 45.44 Million USD | 25.644% |
| Xilio Therapeutics, Inc. | 79.13 Million USD | 57.298% |
| Cardiff Oncology, Inc. | 45.9 Million USD | 26.381% |
| Enanta Pharmaceuticals, Inc. | 216.41 Million USD | 84.386% |
| Regulus Therapeutics Inc. | 9.95 Million USD | -239.369% |
| Moolec Science SA | 52.75 Million USD | 35.942% |
| Acumen Pharmaceuticals, Inc. | 61.13 Million USD | 44.73% |
| LAVA Therapeutics N.V. | 46.54 Million USD | 27.394% |
| Atea Pharmaceuticals, Inc. | 94.07 Million USD | 64.08% |
| Compass Therapeutics, Inc. | 48.47 Million USD | 30.289% |
| Greenwich LifeSciences, Inc. | 9.32 Million USD | -262.259% |
| TFF Pharmaceuticals, Inc. | 22.62 Million USD | -49.329% |
| Humacyte, Inc. | 23.49 Million USD | -43.81% |
| PMV Pharmaceuticals, Inc. | 80.13 Million USD | 57.831% |
| Avenue Therapeutics, Inc. | 14.54 Million USD | -132.4% |
| Genelux Corporation | 24.33 Million USD | -38.858% |
| Trevi Therapeutics, Inc. | 33.92 Million USD | 0.389% |
| Notable Labs, Ltd. | 14.77 Million USD | -128.781% |
| Immunovant, Inc. | 282.7 Million USD | 88.047% |
| Quantum-Si incorporated | 111.65 Million USD | 69.737% |
| DiaMedica Therapeutics Inc. | 21.26 Million USD | -58.889% |
| Vera Therapeutics, Inc. | 102.01 Million USD | 66.875% |
| Acasti Pharma Inc. | 11.3 Million USD | -199.009% |
| MiNK Therapeutics, Inc. | 22.92 Million USD | -47.423% |
| Soleno Therapeutics, Inc. | 41.38 Million USD | 18.348% |
| PepGen Inc. | 84.76 Million USD | 60.136% |
| Nuvectis Pharma, Inc. | 22.89 Million USD | -47.578% |
| BriaCell Therapeutics Corp. | 32.72 Million USD | -3.256% |
| Immuneering Corporation | 58.41 Million USD | 42.151% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -563.84% |
| Belite Bio, Inc | 31.66 Million USD | -6.704% |
| XOMA Corporation | 46.46 Million USD | 27.273% |
| ARS Pharmaceuticals, Inc. | 67.55 Million USD | 49.976% |
| Bionomics Limited | 17.89 Billion USD | 99.811% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 194.706% |
| uniQure N.V. | 285.08 Million USD | 88.147% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -362.251% |
| Poseida Therapeutics, Inc. | 194.2 Million USD | 82.601% |
| Forte Biosciences, Inc. | 32.47 Million USD | -4.046% |
| Anebulo Pharmaceuticals, Inc. | 8.3 Million USD | -306.691% |
| Enlivex Therapeutics Ltd. | 29.39 Million USD | -14.955% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -507.533% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -137.797% |
| FibroBiologics, Inc. Common Stock | 8.88 Million USD | -280.144% |
| Altimmune, Inc. | 30.55 Million USD | -10.587% |
| LENZ Therapeutics, Inc. | 70.7 Million USD | 52.207% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 194.706% |
| Peak Bio, Inc. | 1249.13 USD | -2705062.793% |
| Zevra Therapeutics, Inc. | 74.12 Million USD | 54.41% |
| Benitec Biopharma Inc. | 22.38 Million USD | -50.974% |
| Spyre Therapeutics, Inc. | 243.18 Million USD | 86.105% |
| NKGen Biotech, Inc. Common Stock | 28.54 Million USD | -18.386% |
| Zura Bio Limited | 62.63 Million USD | 46.054% |
| PolyPid Ltd. | 21.04 Million USD | -60.565% |
| NKGen Biotech, Inc. Warrants | 28.54 Million USD | -18.386% |
| argenx SE | 1.53 Billion USD | 97.797% |
| Immunome, Inc. | 122.82 Million USD | 72.487% |
| Verona Pharma plc | 67.15 Million USD | 49.679% |
| enGene Holdings Inc. Warrants | 25.88 Million USD | -30.543% |
| Shattuck Labs, Inc. | 93.61 Million USD | 63.904% |
| CervoMed Inc. | 14.95 Million USD | -125.909% |
| Plus Therapeutics, Inc. | 8.54 Million USD | -295.494% |
| Dianthus Therapeutics, Inc. | 51 Million USD | 33.743% |
| Moolec Science SA | 52.75 Million USD | 35.942% |
| Enveric Biosciences, Inc. | 16.44 Million USD | -105.436% |
| Design Therapeutics, Inc. | 78.19 Million USD | 56.783% |
| Leap Therapeutics, Inc. | 87.04 Million USD | 61.178% |
| Seelos Therapeutics, Inc. | 12.58 Million USD | -168.502% |
| Achilles Therapeutics plc | 75.25 Million USD | 55.098% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -1052.103% |
| CG Oncology, Inc. Common stock | 55.65 Million USD | 39.283% |
| Fractyl Health, Inc. Common Stock | 50.87 Million USD | 33.586% |
| Rani Therapeutics Holdings, Inc. | 66.09 Million USD | 48.878% |
| MoonLake Immunotherapeutics | 54.12 Million USD | 37.566% |
| Tourmaline Bio, Inc. | 45.4 Million USD | 25.585% |
| Beam Therapeutics Inc. | 554.19 Million USD | 93.903% |
| Mirum Pharmaceuticals, Inc. | 248.48 Million USD | 86.401% |
| AEON Biopharma, Inc. | 48.42 Million USD | 30.226% |
| Aadi Bioscience, Inc. | 93.47 Million USD | 63.851% |
| Enliven Therapeutics, Inc. | 83.52 Million USD | 59.546% |
| Kiora Pharmaceuticals, Inc. | 12.58 Million USD | -168.462% |
| NeurAxis, Inc. | 8.82 Million USD | -283.066% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | 92.507% |
| Lumos Pharma, Inc. | 38.66 Million USD | 12.606% |
| Opiant Pharmaceuticals, Inc. | 26.5 Million USD | -27.501% |
| Palisade Bio, Inc. | 13.32 Million USD | -153.686% |
| Nutriband Inc. | 5.73 Million USD | -489.306% |
| Taysha Gene Therapies, Inc. | 87.89 Million USD | 61.553% |
| Neurogene Inc. | 55.58 Million USD | 39.206% |
| Kintara Therapeutics, Inc. | 8.45 Million USD | -299.846% |
| CARGO Therapeutics, Inc. Common Stock | 96.71 Million USD | 65.059% |
| Athira Pharma, Inc. | 125.46 Million USD | 73.068% |
| HCW Biologics Inc. | 21.02 Million USD | -60.699% |
| XOMA Corporation | 46.46 Million USD | 27.273% |
| Nektar Therapeutics | 190.9 Million USD | 82.299% |
| Arvinas, Inc. | 480 Million USD | 92.96% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -1385.991% |
| Merus N.V. | 200.49 Million USD | 83.146% |
| Omega Therapeutics, Inc. | 103.35 Million USD | 67.306% |
| Quince Therapeutics, Inc. | 34.62 Million USD | 2.395% |
| Rezolute, Inc. | 70.38 Million USD | 51.993% |
| Clene Inc. | 41.07 Million USD | 17.729% |
| Indaptus Therapeutics, Inc. | 16.37 Million USD | -106.313% |
| BeyondSpring Inc. | 24.86 Million USD | -35.898% |
| Synlogic, Inc. | 58.53 Million USD | 42.269% |
| Allarity Therapeutics, Inc. | 17.89 Million USD | -88.861% |
| Phio Pharmaceuticals Corp. | 4.49 Million USD | -652.248% |
| Peak Bio, Inc. | 1249.13 USD | -2705062.793% |
| Werewolf Therapeutics, Inc. | 60.44 Million USD | 44.097% |
| Krystal Biotech, Inc. | 160.42 Million USD | 78.937% |
| Karyopharm Therapeutics Inc. | 270.63 Million USD | 87.514% |
| SpringWorks Therapeutics, Inc. | 348.03 Million USD | 90.291% |
| Lipella Pharmaceuticals Inc. | 2.15 Million USD | -1466.767% |
| MannKind Corporation | 125.59 Million USD | 73.096% |
| Ikena Oncology, Inc. | 84.57 Million USD | 60.047% |
| Cyclerion Therapeutics, Inc. | 9.64 Million USD | -250.275% |
| Gyre Therapeutics, Inc. | 89.6 Million USD | 62.287% |
| Gossamer Bio, Inc. | 183.75 Million USD | 81.611% |
| CohBar, Inc. | 12.38 Million USD | -172.765% |
| Cognition Therapeutics, Inc. | 50.72 Million USD | 33.383% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -22.511% |
| Legend Biotech Corporation | 583.14 Million USD | 94.205% |
| Mural Oncology plc | 192.07 Million USD | 82.407% |
| Disc Medicine, Inc. | 91.12 Million USD | 62.918% |
| Champions Oncology, Inc. | 28.11 Million USD | -20.21% |
| REGENXBIO Inc. | 321.15 Million USD | 89.478% |
| Ensysce Biosciences, Inc. | 5.36 Million USD | -530.284% |
| Anavex Life Sciences Corp. | 55.75 Million USD | 39.395% |
| Cellectar Biosciences, Inc. | 38.96 Million USD | 13.269% |
| Edgewise Therapeutics, Inc. | 114.35 Million USD | 70.451% |
| Vaxart, Inc. | 90.72 Million USD | 62.755% |
| PharmaCyte Biotech, Inc. | 8.52 Million USD | -296.608% |
| Aldeyra Therapeutics, Inc. | 42.79 Million USD | 21.038% |
| Cellectis S.A. | 97.32 Million USD | 65.278% |
| Longeveron Inc. | 21.25 Million USD | -59.016% |
| Repare Therapeutics Inc. | 167.35 Million USD | 79.809% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 97.517% |
| Inozyme Pharma, Inc. | 75.64 Million USD | 55.329% |
| Revolution Medicines, Inc. | 498.76 Million USD | 93.225% |
| Nymox Pharmaceutical Corporation | 6.65 Million USD | -407.983% |
| Third Harmonic Bio, Inc. | 43.95 Million USD | 23.122% |
| ArriVent BioPharma, Inc. Common Stock | 74.59 Million USD | 54.698% |
| AN2 Therapeutics, Inc. | 69.63 Million USD | 51.474% |
| Anixa Biosciences, Inc. | 11.06 Million USD | -205.524% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 99.292% |
| Denali Therapeutics Inc. | 527.23 Million USD | 93.591% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -290.347% |
| Veru Inc. | 101.34 Million USD | 66.658% |
| Corvus Pharmaceuticals, Inc. | 23.4 Million USD | -44.363% |
| Cingulate Inc. | 22.75 Million USD | -48.472% |
| Passage Bio, Inc. | 108.38 Million USD | 68.824% |
| Context Therapeutics Inc. | 25.07 Million USD | -34.773% |
| Exicure, Inc. | 14.07 Million USD | -140.061% |
| Day One Biopharmaceuticals, Inc. | 206.06 Million USD | 83.602% |
| Oramed Pharmaceuticals Inc. | 43.3 Million USD | 21.963% |
| Scinai Immunotherapeutics Ltd. | 9.17 Million USD | -268.202% |
| Nuvalent, Inc. | 149.49 Million USD | 77.396% |
| ABVC BioPharma, Inc. | 8.06 Million USD | -318.884% |
| Carisma Therapeutics, Inc. | 103.65 Million USD | 67.399% |
| Unicycive Therapeutics, Inc. | 21.44 Million USD | -57.541% |
| OmniAb, Inc. | 83.89 Million USD | 59.722% |
| Anew Medical, Inc. | 1.3 Million USD | -2497.627% |
| Fennec Pharmaceuticals Inc. | 32.76 Million USD | -3.135% |
| Lipocine Inc. | 15.08 Million USD | -124.076% |
| Lexeo Therapeutics, Inc. Common Stock | 68.51 Million USD | 50.679% |
| Nautilus Biotechnology, Inc. | 76.15 Million USD | 55.627% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | 16.181% |
| G1 Therapeutics, Inc. | 114.84 Million USD | 70.576% |
| Bellerophon Therapeutics, Inc. | 22.38 Million USD | -50.961% |
| Sage Therapeutics, Inc. | 664.14 Million USD | 94.912% |
| Ocugen, Inc. | 71.56 Million USD | 52.784% |
| Mind Medicine (MindMed) Inc. | 93.86 Million USD | 64.001% |
| Q32 Bio Inc. | 92.68 Million USD | 63.54% |
| Brainstorm Cell Therapeutics Inc. | 21.17 Million USD | -59.587% |
| Alumis Inc. Common Stock | 158.17 Million USD | 78.637% |
| Equillium, Inc. | 50.6 Million USD | 33.227% |
| Kyverna Therapeutics, Inc. | 62.4 Million USD | 45.853% |
| Coya Therapeutics, Inc. | 13.9 Million USD | -143.004% |
| CNS Pharmaceuticals, Inc. | 18.86 Million USD | -79.119% |
| Dominari Holdings Inc. | 23.83 Million USD | -41.771% |
| Edesa Biotech, Inc. | 9.22 Million USD | -266.387% |
| vTv Therapeutics Inc. | 11.9 Million USD | -183.791% |
| Bio-Techne Corporation | 563.03 Million USD | 93.998% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | 91.734% |
| Harmony Biosciences Holdings, Inc. | 268.75 Million USD | 87.427% |
| Prelude Therapeutics Incorporated | 132.27 Million USD | 74.454% |
| Candel Therapeutics, Inc. | 14.41 Million USD | -134.481% |
| iTeos Therapeutics, Inc. | 163.69 Million USD | 79.357% |
| Nkarta, Inc. | 131.65 Million USD | 74.333% |
| BioCardia, Inc. | 12.12 Million USD | -178.781% |
| Iterum Therapeutics plc | 47.46 Million USD | 28.813% |